
Janux Therapeutics
Developing unique immunotherapies that generate tumor-specific immune responses to attack and kill tumors without destroying a patient’s healthy tissue.
Market cap
$1.4b
Enterprise value
$429m
Share price
$23.05 JANX
Authorizing premium user...